MDXG vs. PRCT, NVST, LIVN, WRBY, NVCR, LMAT, CNMD, ENOV, EYE, and TNDM
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include PROCEPT BioRobotics (PRCT), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), CONMED (CNMD), Enovis (ENOV), National Vision (EYE), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry.
MiMedx Group vs. Its Competitors
MiMedx Group (NASDAQ:MDXG) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.
MiMedx Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, MiMedx Group had 1 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 8 mentions for MiMedx Group and 7 mentions for PROCEPT BioRobotics. MiMedx Group's average media sentiment score of 1.50 beat PROCEPT BioRobotics' score of 0.21 indicating that MiMedx Group is being referred to more favorably in the media.
MiMedx Group currently has a consensus price target of $12.50, suggesting a potential upside of 91.86%. PROCEPT BioRobotics has a consensus price target of $90.00, suggesting a potential upside of 42.60%. Given MiMedx Group's stronger consensus rating and higher probable upside, equities analysts plainly believe MiMedx Group is more favorable than PROCEPT BioRobotics.
79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by company insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
MiMedx Group has a net margin of 23.86% compared to PROCEPT BioRobotics' net margin of -50.07%. MiMedx Group's return on equity of 26.21% beat PROCEPT BioRobotics' return on equity.
MiMedx Group received 10 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. Likewise, 83.87% of users gave MiMedx Group an outperform vote while only 68.85% of users gave PROCEPT BioRobotics an outperform vote.
MiMedx Group has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
Summary
MiMedx Group beats PROCEPT BioRobotics on 14 of the 18 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
This page (NASDAQ:MDXG) was last updated on 6/11/2025 by MarketBeat.com Staff
